TrialNature medicine2026

BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial.

Renee R Fedak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.